CAFs have emerged as crucial mediators of resistance to immune checkpoint blockades (ICBs) across various tumor types, and in some tumor types, PD-L1/PD-L2 expressions on subsets of CAFs are reported, which are features that may contribute to immune dysfunction (Figure 2). The gene discussed is PDCD1LG2; the disease is neoplasm.